pioglitazone has been researched along with Fractures, Bone in 28 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Fractures, Bone: Breaks in bones.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The identification of insulin resistance as a risk factor for stroke and myocardial infarction raised the possibility that pioglitazone, which improves insulin sensitivity, might benefit patients with cerebrovascular disease." | 9.22 | Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. ( Adams, HP; Berger, L; Brass, LM; Carolei, A; Clark, W; Conwit, R; Coull, B; Ford, GA; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kernan, WN; Kleindorfer, D; Lovejoy, AM; O'Leary, JR; Parsons, MW; Peduzzi, PN; Ringleb, P; Schwartz, GG; Sen, S; Spence, JD; Tanne, D; Viscoli, CM; Wang, D; Winder, TR; Young, LH, 2016) |
| "A total of 86 people with type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT), median age 64 years, were randomized to receive either pioglitazone 30 mg/day or placebo for 1 year, in addition to their usual diabetes treatments." | 9.19 | The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. ( Bolland, M; Drury, PL; Fenwick, S; Gamble, G; Grey, A; Horne, A; Reid, IR, 2014) |
| "This study examined the effects of pioglitazone on body weight and bone mineral density (BMD) prospectively in patients with impaired glucose tolerance as pioglitazone (TZD) increases body weight and body fat in diabetic patients and increases the risk of bone fractures." | 9.17 | Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. ( Banerji, MA; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Kitabchi, AE; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Schwenke, DC; Smith, SR; Stentz, FB; Tripathy, D, 2013) |
| "To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2 diabetes." | 8.95 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. ( Chen, TH; Lee, M; Liao, HW; Ovbiagele, B; Saver, JL; Wu, YL, 2017) |
| "The prevalence of type 2 diabetes (T2DM) in elderly people has expanded rapidly." | 5.91 | Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study. ( Jenq, CC; Lee, CC; Li, YJ; Liu, JR; Liu, YC; Peng, WS; See, LC; Tsai, CY; Wu, CY; Yang, HY; Yen, CL, 2023) |
| "Patients were 3876 nondiabetic participants in the Insulin Resistance Intervention after Stroke trial randomized to pioglitazone or placebo and followed for a median of 4." | 5.24 | Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. ( Conwit, R; Furie, KL; Gorman, M; Insogna, KL; Inzucchi, SE; Kelly, MA; Kernan, WN; Lovejoy, AM; Viscoli, CM; Young, LH, 2017) |
| " The identification of insulin resistance as a risk factor for stroke and myocardial infarction raised the possibility that pioglitazone, which improves insulin sensitivity, might benefit patients with cerebrovascular disease." | 5.22 | Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. ( Adams, HP; Berger, L; Brass, LM; Carolei, A; Clark, W; Conwit, R; Coull, B; Ford, GA; Furie, KL; Gorman, M; Guarino, PD; Inzucchi, SE; Kernan, WN; Kleindorfer, D; Lovejoy, AM; O'Leary, JR; Parsons, MW; Peduzzi, PN; Ringleb, P; Schwartz, GG; Sen, S; Spence, JD; Tanne, D; Viscoli, CM; Wang, D; Winder, TR; Young, LH, 2016) |
| "A total of 86 people with type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT), median age 64 years, were randomized to receive either pioglitazone 30 mg/day or placebo for 1 year, in addition to their usual diabetes treatments." | 5.19 | The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. ( Bolland, M; Drury, PL; Fenwick, S; Gamble, G; Grey, A; Horne, A; Reid, IR, 2014) |
| "This study examined the effects of pioglitazone on body weight and bone mineral density (BMD) prospectively in patients with impaired glucose tolerance as pioglitazone (TZD) increases body weight and body fat in diabetic patients and increases the risk of bone fractures." | 5.17 | Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial. ( Banerji, MA; Bray, GA; Buchanan, TA; Clement, SC; DeFronzo, RA; Henry, RR; Kitabchi, AE; Mudaliar, S; Musi, N; Ratner, RE; Reaven, PD; Schwenke, DC; Smith, SR; Stentz, FB; Tripathy, D, 2013) |
| "ru electronic databases and clinical trial registries for studies reporting an association between pioglitazone and bone fractures in type 2 diabetes mellitus patients published before Feb 15, 2016." | 4.98 | Pioglitazone Therapy and Fractures: Systematic Review and Meta- Analysis. ( Filipova, E; Kalinov, K; Pavlova, V; Uzunova, K; Vekov, T, 2018) |
| "To evaluate the effect of pioglitazone in people with insulin resistance, pre-diabetes and type 2 diabetes." | 4.95 | Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. ( Chen, TH; Lee, M; Liao, HW; Ovbiagele, B; Saver, JL; Wu, YL, 2017) |
| " In particular, Food and Drug Administration of the United States Department of Health and Human Service (FDA) noted that rosiglitazone and pioglitazone, PPAR gamma agonists, have an increased risk of bone fractures." | 4.85 | [Relationship between insulin resistance and bone metabolism]. ( Hamada, Y, 2009) |
| "Compared with insulin, pioglitazone was associated with a significant reduction in the risk of MI and stroke requiring hospitalization, and a significant reduction in the risk of other selected cancers." | 3.79 | Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights. ( Bron, M; Fusco, G; Joseph, G; Liang, H; Manne, S; Perez, A; Vallarino, C; Yu, S, 2013) |
| "Rosiglitazone was used by 74% and pioglitazone by 13% of participants." | 2.80 | Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study. ( Ambrosius, WT; Banerji, MA; Bauer, DC; Bonds, DE; Chen, H; Cohen, RM; Hamilton, BP; Isakova, T; Josse, RG; Margolis, KL; Schnall, AM; Schwartz, AV; Sellmeyer, DE; Shibli-Rahhal, A; Simmons, DL; Sood, A; Vittinghoff, E; Williamson, JD, 2015) |
| "Pioglitazone therapy was shown to significantly reduce the BMD of the whole body, lumbar spine, and total hip and serum PTH levels and increase BMI, total body fat mass and leg fat mass." | 2.61 | Pioglitazone Therapy Decreases Bone Mass Density and Increases Fat Mass: A Meta-Analysis. ( Wang, J; Zhang, N; Zuo, L, 2019) |
| "Pioglitazone is a thiazolidinedione that displays high affinity for PPARγ(1) and PPARγ(2), which are predominately expressed in adipose tissue." | 2.46 | Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents. ( Derosa, G, 2010) |
| "The prevalence of type 2 diabetes (T2DM) in elderly people has expanded rapidly." | 1.91 | Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study. ( Jenq, CC; Lee, CC; Li, YJ; Liu, JR; Liu, YC; Peng, WS; See, LC; Tsai, CY; Wu, CY; Yang, HY; Yen, CL, 2023) |
| ": The aim of the study was to verify if the analysis of a large spontaneous reporting database could generate early signals on these adverse drug reactions (ADRs) associated with TZDs." | 1.38 | Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database. ( Biagi, C; Marchesini, G; Marra, A; Motola, D; Piccinni, C; Poluzzi, E; Raschi, E, 2012) |
| "Pioglitazone was associated with reduced all cause mortality compared with metformin." | 1.35 | Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. ( Curcin, V; Elliott, P; Hughes, RI; Khunti, K; Little, MP; Majeed, A; Millett, CJ; Molokhia, M; Ng, A; Tzoulaki, I; Wilkins, MR, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 12 (42.86) | 29.6817 |
| 2010's | 15 (53.57) | 24.3611 |
| 2020's | 1 (3.57) | 2.80 |
| Authors | Studies |
|---|---|
| Yen, CL | 1 |
| Wu, CY | 1 |
| Tsai, CY | 1 |
| Lee, CC | 1 |
| Li, YJ | 1 |
| Peng, WS | 1 |
| Liu, JR | 1 |
| Liu, YC | 1 |
| Jenq, CC | 1 |
| Yang, HY | 1 |
| See, LC | 1 |
| Zuo, L | 1 |
| Wang, J | 2 |
| Zhang, N | 1 |
| Pavlova, V | 1 |
| Filipova, E | 1 |
| Uzunova, K | 1 |
| Kalinov, K | 1 |
| Vekov, T | 1 |
| Bray, GA | 1 |
| Smith, SR | 1 |
| Banerji, MA | 2 |
| Tripathy, D | 1 |
| Clement, SC | 1 |
| Buchanan, TA | 1 |
| Henry, RR | 1 |
| Kitabchi, AE | 1 |
| Mudaliar, S | 1 |
| Musi, N | 1 |
| Ratner, RE | 1 |
| Schwenke, DC | 1 |
| Stentz, FB | 1 |
| Reaven, PD | 1 |
| DeFronzo, RA | 1 |
| Vallarino, C | 1 |
| Perez, A | 1 |
| Fusco, G | 1 |
| Liang, H | 1 |
| Bron, M | 1 |
| Manne, S | 1 |
| Joseph, G | 1 |
| Yu, S | 1 |
| Grey, A | 1 |
| Bolland, M | 1 |
| Fenwick, S | 1 |
| Horne, A | 1 |
| Gamble, G | 1 |
| Drury, PL | 1 |
| Reid, IR | 1 |
| Schwartz, AV | 1 |
| Chen, H | 1 |
| Ambrosius, WT | 1 |
| Sood, A | 1 |
| Josse, RG | 1 |
| Bonds, DE | 1 |
| Schnall, AM | 1 |
| Vittinghoff, E | 1 |
| Bauer, DC | 1 |
| Cohen, RM | 1 |
| Hamilton, BP | 1 |
| Isakova, T | 1 |
| Sellmeyer, DE | 1 |
| Simmons, DL | 1 |
| Shibli-Rahhal, A | 1 |
| Williamson, JD | 1 |
| Margolis, KL | 1 |
| Kernan, WN | 2 |
| Viscoli, CM | 2 |
| Furie, KL | 2 |
| Young, LH | 2 |
| Inzucchi, SE | 2 |
| Gorman, M | 2 |
| Guarino, PD | 1 |
| Lovejoy, AM | 2 |
| Peduzzi, PN | 1 |
| Conwit, R | 2 |
| Brass, LM | 1 |
| Schwartz, GG | 1 |
| Adams, HP | 1 |
| Berger, L | 1 |
| Carolei, A | 1 |
| Clark, W | 1 |
| Coull, B | 1 |
| Ford, GA | 1 |
| Kleindorfer, D | 1 |
| O'Leary, JR | 1 |
| Parsons, MW | 1 |
| Ringleb, P | 1 |
| Sen, S | 1 |
| Spence, JD | 1 |
| Tanne, D | 1 |
| Wang, D | 1 |
| Winder, TR | 1 |
| Insogna, KL | 1 |
| Kelly, MA | 1 |
| Liao, HW | 1 |
| Saver, JL | 1 |
| Wu, YL | 1 |
| Chen, TH | 1 |
| Lee, M | 1 |
| Ovbiagele, B | 1 |
| Kenny, C | 1 |
| Lipscombe, LL | 1 |
| Loke, YK | 1 |
| Singh, S | 1 |
| Furberg, CD | 1 |
| Toulis, KA | 1 |
| Goulis, DG | 1 |
| Anastasilakis, AD | 1 |
| Viljoen, A | 1 |
| Sinclair, A | 1 |
| Hamada, Y | 1 |
| Douglas, IJ | 1 |
| Evans, SJ | 1 |
| Pocock, S | 1 |
| Smeeth, L | 1 |
| Dixit, A | 1 |
| Pandey, P | 1 |
| Tzoulaki, I | 1 |
| Molokhia, M | 1 |
| Curcin, V | 1 |
| Little, MP | 1 |
| Millett, CJ | 1 |
| Ng, A | 1 |
| Hughes, RI | 1 |
| Khunti, K | 1 |
| Wilkins, MR | 1 |
| Majeed, A | 1 |
| Elliott, P | 1 |
| Aubert, RE | 1 |
| Herrera, V | 1 |
| Chen, W | 1 |
| Haffner, SM | 1 |
| Pendergrass, M | 1 |
| Bilik, D | 1 |
| McEwen, LN | 1 |
| Brown, MB | 1 |
| Pomeroy, NE | 1 |
| Kim, C | 1 |
| Asao, K | 1 |
| Crosson, JC | 1 |
| Duru, OK | 1 |
| Ferrara, A | 1 |
| Hsiao, VC | 1 |
| Karter, AJ | 1 |
| Lee, PG | 1 |
| Marrero, DG | 1 |
| Selby, JV | 1 |
| Subramanian, U | 1 |
| Herman, WH | 1 |
| Derosa, G | 1 |
| Kurra, S | 1 |
| Siris, E | 1 |
| Motola, D | 1 |
| Piccinni, C | 1 |
| Biagi, C | 1 |
| Raschi, E | 1 |
| Marra, A | 1 |
| Marchesini, G | 1 |
| Poluzzi, E | 1 |
| Beck, GR | 1 |
| Khazai, NB | 1 |
| Bouloux, GF | 1 |
| Camalier, CE | 1 |
| Lin, Y | 1 |
| Garneys, LM | 1 |
| Siqueira, J | 1 |
| Peng, L | 1 |
| Pasquel, F | 1 |
| Umpierrez, D | 1 |
| Smiley, D | 1 |
| Umpierrez, GE | 1 |
| Hampton, T | 1 |
| Meymeh, RH | 1 |
| Wooltorton, E | 1 |
| Eckert, S | 1 |
| Erdmann, E | 1 |
| Lundershausen, R | 1 |
| Forst, T | 1 |
| Scherbaum, WA | 1 |
| Schnell, O | 1 |
| Standl, E | 1 |
| Schumm-Draeger, PM | 1 |
| Tschöpe, D | 1 |
| Walter, H | 1 |
| Weber, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Intensive Glycemic Control and Skeletal Health Study - Ancillary Study to the Action to Control Cardiovascular Risk in Diabetes Trial (ACCORD-BONE)[NCT00324350] | Phase 3 | 7,287 participants (Actual) | Interventional | 2003-10-31 | Completed | ||
| Preventive Effects of Ginseng Against Atherosclerosis and Subsequent Ischemic Stroke: A Randomized Controlled Trial[NCT02796664] | 58 participants (Actual) | Interventional | 2016-06-23 | Completed | |||
| Insulin Resistance Intervention After Stroke (IRIS) Trial[NCT00091949] | Phase 3 | 3,876 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients[NCT01386671] | Phase 3 | 203 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Effects of Thiazolidinediones on Human Bone Marrow Stromal Cell Differentiation Capacity:In Vitro and In Vivo- A Pilot Study[NCT00927355] | 10 participants (Actual) | Interventional | 2009-04-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Standing height was measured according to a standard protocol at baseline and annual visits on all ACCORD participants. Height loss was compared by treatment assignment using linear mixed models with random intercepts and slopes. Treatment effects were captured by the interaction between treatment assignment and time. The proportions losing >2 cm of height during follow-up were compared using logistic models. This degree of height loss is associated with incident vertebral fracture with 94% specificity but only 28% sensitivity (NCT00324350)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Intensive Glycemic Control | 678 |
| Standard Glycemic Control | 686 |
"At each annual visit starting in January 2006, participants were also asked about falling: In the last 12 months have you fallen and landed on the floor or ground, OR fallen and hit an object like a table or stair? Those who answered yes were also asked how many times they had fallen in the previous 12 months." (NCT00324350)
Timeframe: Average follow-up of 2.0 years
| Intervention | participants (Number) |
|---|---|
| Intensive Glycemic Control | 1122 |
| Standard Glycemic Control | 1133 |
The BONE ancillary study was initiated during recruitment for the main ACCORD trial. Beginning in January 2006, at the next annual visit participants were asked about the occurrence of any non-spine fractures since randomization. After the annual visit in 2006, participants were asked if they had suffered a fracture since their last annual visit. Reported fracture events were centrally adjudicated, based on radiology records, at the University of California, San Francisco (UCSF) with the adjudicators blinded to treatment assignment. (NCT00324350)
Timeframe: Average follow-up of 3.8 years
| Intervention | participants (Number) |
|---|---|
| Intensive Glycemic Control | 198 |
| Standard Glycemic Control | 189 |
We calculated average drug compliance based on the number of remained drugs at each follow-up. (NCT02796664)
Timeframe: At twelve months after randomization.
| Intervention | percentage of drug compliance (Mean) |
|---|---|
| Ginseng | 97.4 |
| Placebo | 97.8 |
Presence of other cerebro-cardiovascular morbidity or mortality assessed by aggravation of patient status (modified Rankin Scale). The modified Rankin Scale is ranging from 0 to 5. The higher scale indicates the worse outcome. (NCT02796664)
Timeframe: Twelve months after randomization.
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| mRS 0 | mRS 1 | mRS 2 | mRS 3 | mRS 4 | mRS 5 | |
| Ginseng | 21 | 5 | 0 | 2 | 0 | 0 |
| Placebo | 22 | 1 | 0 | 1 | 0 | 0 |
The 1-year composite of cerebral ischemic stroke and transient ischemic attack downstream to an atherosclerotic lesion (NCT02796664)
Timeframe: Twelve months after randomization.
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Ischemic stroke | Transient ischemic attack | |
| Ginseng | 0 | 0 |
| Placebo | 0 | 1 |
The changes in volumetric blood flow (ml/sec) in intracranial vessels assessed by quantitative magnetic resonance angiography with noninvasive optimal vessel analysis. (NCT02796664)
Timeframe: At randomization and twelve months after randomization.
| Intervention | Participants (Count of Participants) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| The flow change in steno-occlusive lesion72501839 | The flow change in steno-occlusive lesion72501838 | The flow change in collateral vessel72501838 | The flow change in collateral vessel72501839 | |||||||||
| Improved | No change | Aggravated | ||||||||||
| Ginseng | 4 | |||||||||||
| Placebo | 5 | |||||||||||
| Ginseng | 17 | |||||||||||
| Placebo | 18 | |||||||||||
| Placebo | 1 | |||||||||||
| Ginseng | 7 | |||||||||||
| Placebo | 7 | |||||||||||
| Placebo | 9 | |||||||||||
| Placebo | 8 | |||||||||||
The changes of white matter hyperintensities, assessed by the Fazekas scale using brain magnetic resonance imaging. The Fazekas scale is a 4 point white matter disease severity scale with values ranging from 0 to 3. It quantifies the amount of white matter T2 hyperintense lesions each in periventricular white matter and deep white matter. Higher scales mean a worse white matter status. In the region of the periventricular white matter, 0 means absence of the lesion; 1, caps or pencil-thin lining lesion; 2, smooth halo lesion; 3, irregular high intense signal extending into the deep shite matter. In the region of the deep white matter, 0 means absence of the lesion; 1, punctate foci lesions; 2, beginning confluence; 3, large confluent hyperintense areas. (NCT02796664)
Timeframe: At randomization and twelve months after randomization.
| Intervention | Participants (Count of Participants) | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Periventricular white matter72501836 | Periventricular white matter72501837 | Deep white matter72501837 | Deep white matter72501836 | |||||||||||||
| Fazekas scale 3 | Fazekas scale 0 | Fazekas scale 1 | Fazekas scale 2 | |||||||||||||
| Placebo | 11 | |||||||||||||||
| Placebo | 10 | |||||||||||||||
| Ginseng | 2 | |||||||||||||||
| Ginseng | 9 | |||||||||||||||
| Placebo | 6 | |||||||||||||||
| Ginseng | 15 | |||||||||||||||
| Placebo | 15 | |||||||||||||||
| Ginseng | 3 | |||||||||||||||
| Placebo | 2 | |||||||||||||||
| Ginseng | 1 | |||||||||||||||
| Placebo | 1 | |||||||||||||||
Fatal or non-fatal acute myocardial infarction or unstable angina (NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 136 |
| Placebo | 146 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 206 |
| Placebo | 249 |
Change in modified mental status examination (3MS) score from baseline to exit. Theoretical range of 3MS scores is 0-100. Baseline scores ranged from 22-100. (NCT00091949)
Timeframe: Annual measures from baseline to exit (up to 5 years)
| Intervention | units on a scale (Mean) |
|---|---|
| Pioglitazone | 0.27 |
| Placebo | 0.29 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 73 |
| Placebo | 149 |
(NCT00091949)
Timeframe: 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 127 |
| Placebo | 154 |
(NCT00091949)
Timeframe: Up to 5 years
| Intervention | participants (Number) |
|---|---|
| Pioglitazone | 175 |
| Placebo | 228 |
(NCT00927355)
Timeframe: 6 months
| Intervention | percent change from baseline to 6 months (Mean) |
|---|---|
| Pioglitazone-Femoral Neck BMD | -4 |
| Placebo-Femoral Neck BMD | -2.6 |
| Pioglitazone -Lumbar Spine BMD | -1.1 |
| Placebo - Lumbar Spine BMD | 1.9 |
To determine the effect of PIO (pioglitazone) on BMSC (bone marrow stem cell) lineage choice in vivo, a bone marrow aspiration was obtained from patients at baseline and after 6 months of treatment with PIO or placebo. The bone marrow was used for ex vivo CFU-OB (Colony forming units-Osteoblast) and CFU-AD assays using the same protocol described for the in vitro studies previously. We also analyzed the number of total colonies per patient at both baseline and final visit. (NCT00927355)
Timeframe: 6 months
| Intervention | percent change from baseline to 6months (Mean) |
|---|---|
| Pioglitazone-Osteoblast CFU (Colony Forming Units) | 0 |
| Placebo-OSteoblast CFU | 12 |
| Pioglitazone-Adipocyte CFU | 4 |
| Placebo-Adipocyte CFU | -7 |
(NCT00927355)
Timeframe: 6 months
| Intervention | percent change from baseline (Mean) |
|---|---|
| Pioglitazone-Adiponectin | 78.7 |
| Placebo-Adiponectin | -0.6 |
| Pioglitazone-CTX | -9.2 |
| Placebo-CTX | 0.2 |
| Pioglitazone-OSc | 3.6 |
| Placebo - Osc | -5 |
8 reviews available for pioglitazone and Fractures, Bone
| Article | Year |
|---|---|
Pioglitazone Therapy Decreases Bone Mass Density and Increases Fat Mass: A Meta-Analysis.
Topics: Adiposity; Body Mass Index; Bone and Bones; Bone Density; Diabetes Mellitus, Type 2; Fractures, Bone | 2019 |
Pioglitazone Therapy and Fractures: Systematic Review and Meta- Analysis.
Topics: Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Incidence; Male; Pi | 2018 |
Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis.
Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Edema; Fractures, Bone; Humans; Hypoglycemic Age | 2017 |
Rosiglitazone and the thiazolidinediones: a changing context.
Topics: Fractures, Bone; Heart Failure; Humans; Hypoglycemic Agents; Pioglitazone; Risk Factors; Rosiglitazo | 2007 |
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis.
Topics: Bone Density; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; | 2009 |
Safety and efficacy of rosiglitazone in the elderly diabetic patient.
Topics: Age Factors; Aged; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Fra | 2009 |
[Relationship between insulin resistance and bone metabolism].
Topics: Adipokines; Animals; Bone and Bones; Carbohydrate Metabolism; Fractures, Bone; Humans; Hypoglycemic | 2009 |
Efficacy and tolerability of pioglitazone in patients with type 2 diabetes mellitus: comparison with other oral antihyperglycaemic agents.
Topics: Administration, Oral; Blood Glucose; Cardiovascular System; Diabetes Mellitus, Type 2; Edema; Fractu | 2010 |
6 trials available for pioglitazone and Fractures, Bone
| Article | Year |
|---|---|
Effect of pioglitazone on body composition and bone density in subjects with prediabetes in the ACT NOW trial.
Topics: Absorptiometry, Photon; Adipose Tissue; Body Mass Index; Body Weight; Bone Density; Diabetes Mellitu | 2013 |
The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Bone Density; Bone Density Conservation Agents; Bone Remodeling; Dia | 2014 |
Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study.
Topics: Aged; Cohort Studies; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Fractures, Bone; Humans; | 2015 |
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Brain Ischemia; Double-Blind Method; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Ins | 2016 |
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Brain Ischemia; Double-Blind Method; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Ins | 2016 |
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Brain Ischemia; Double-Blind Method; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Ins | 2016 |
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
Topics: Aged; Brain Ischemia; Double-Blind Method; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Ins | 2016 |
Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial.
Topics: Accidental Falls; Aged; Double-Blind Method; Female; Fractures, Bone; Humans; Hypoglycemic Agents; I | 2017 |
The effects of thiazolidinediones on human bone marrow stromal cell differentiation in vitro and in thiazolidinedione-treated patients with type 2 diabetes.
Topics: Adipocytes; Adipogenesis; Bone Density; Cell Differentiation; Colony-Forming Units Assay; Diabetes M | 2013 |
14 other studies available for pioglitazone and Fractures, Bone
| Article | Year |
|---|---|
Pioglitazone reduces cardiovascular events and dementia but increases bone fracture in elderly patients with type 2 diabetes mellitus: a national cohort study.
Topics: Aged; Cardiovascular Diseases; Cohort Studies; Dementia; Diabetes Mellitus, Type 2; Fractures, Bone; | 2023 |
Comparing pioglitazone to insulin with respect to cancer, cardiovascular and bone fracture endpoints, using propensity score weights.
Topics: Aged; Aged, 80 and over; Cohort Studies; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Insul | 2013 |
Thiazolidinediones: do harms outweigh benefits?
Topics: Bone Density; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; | 2009 |
Thiazolidinedione use and the risk of fractures.
Topics: Bone Density; Case-Control Studies; Confidence Intervals; Diabetes Mellitus, Type 2; Female; Follow- | 2009 |
The risk of fractures associated with thiazolidinediones: a self-controlled case-series study.
Topics: Aged; Bone and Bones; Case-Control Studies; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2009 |
Rosiglitazone and pioglitazone. Beware fractures.
Topics: Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Pioglitazone; | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.
Topics: Administration, Oral; Aged; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Fractures, Bon | 2009 |
Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes.
Topics: Adult; Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Incidence; M | 2010 |
Thiazolidinediones and fractures: evidence from translating research into action for diabetes.
Topics: Adult; Aged; Case-Control Studies; Diabetes Mellitus, Type 2; Evidence-Based Medicine; Female; Fract | 2010 |
Diabetes and bone health: the relationship between diabetes and osteoporosis-associated fractures.
Topics: Accidental Falls; Bone and Bones; Diabetes Complications; Diabetes Mellitus, Type 1; Diabetes Mellit | 2011 |
Cardiovascular, ocular and bone adverse reactions associated with thiazolidinediones: a disproportionality analysis of the US FDA adverse event reporting system database.
Topics: Adverse Drug Reaction Reporting Systems; Bone and Bones; Cardiovascular System; Clinical Trials as T | 2012 |
Diabetes drugs tied to fractures in women.
Topics: Chromans; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Pioglitazone; Rosiglitazone; Thiazol | 2007 |
Diabetes drug pioglitazone (Actos): risk of fracture.
Topics: Diabetes Mellitus, Type 2; Female; Fractures, Bone; Humans; Hypoglycemic Agents; Male; Osteoporosis; | 2007 |
[Determining the current position regarding the value of pioglitazone for the therapy of diabetes].
Topics: Animals; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Dyslipidemias; Fractures, Bone; Glycate | 2007 |